A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Inclusion Criteria: * Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who have not received any bisphosphonates in the 12 months prior to enrollment * 18 years old and over Exclusion Criteria: * Plan to be on cytotoxic or biologic therapy during study * Active dental problems * Active heart complications * Active infection * Patients with moderate to severe swelling due to fluid Other protocol-defined inclusion/exclusion criteria may apply